TG Therapeutics (NASDAQ:TGTX) Hits New 12-Month High – What’s Next?

TG Therapeutics, Inc. (NASDAQ:TGTX)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $43.32 and last traded at $42.61, with a volume of 2055275 shares trading hands. The stock had previously closed at $42.99.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on TGTX shares. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Price Performance

The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock’s 50 day moving average price is $33.47 and its two-hundred day moving average price is $29.89. The firm has a market capitalization of $6.69 billion, a price-to-earnings ratio of -426.06 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Activity at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares in the company, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

A number of large investors have recently bought and sold shares of the business. Victory Capital Management Inc. boosted its stake in shares of TG Therapeutics by 24.7% during the 3rd quarter. Victory Capital Management Inc. now owns 32,679 shares of the biopharmaceutical company’s stock worth $764,000 after acquiring an additional 6,467 shares in the last quarter. Mutual of America Capital Management LLC bought a new stake in TG Therapeutics during the third quarter worth approximately $469,000. Thrivent Financial for Lutherans acquired a new position in TG Therapeutics during the third quarter valued at approximately $2,450,000. Quest Partners LLC bought a new position in shares of TG Therapeutics in the third quarter valued at approximately $246,000. Finally, Intech Investment Management LLC acquired a new stake in shares of TG Therapeutics in the third quarter worth $1,129,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.